These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11480224)

  • 21. Bispectral Index in the sedation with intranasal midazolam and intravenous diazepam in dental practice.
    Manani G; Facco E; Cordioli A; Guarda-Nardini L; Berengo M; Mazzuchin M; Da Corte Zandatina S; Fontana G; Tonello S; Malimpensa B; Zanette G
    Minerva Stomatol; 2007 Mar; 56(3):85-104. PubMed ID: 17327813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of the abuse liability of buspirone in alcohol-dependent patients.
    Griffith JD; Jasinski DR; Casten GP; McKinney GR
    Am J Med; 1986 Mar; 80(3B):30-5. PubMed ID: 3963032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of the abuse liability of alprazolam, lorazepam, diazepam, methaqualone, and placebo.
    Orzack MH; Friedman L; Dessain E; Bird M; Beake B; McEachern J; Cole JO
    Int J Addict; 1988 May; 23(5):449-67. PubMed ID: 3061941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.
    Griffiths RR; Johnson MW
    J Clin Psychiatry; 2005; 66 Suppl 9():31-41. PubMed ID: 16336040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Differences in the subjective effects of drugs in patients with a first psychotic episode. Preliminary results].
    Busquets E; Torrens M; Soler A; Farré M; Bulbena A
    Actas Esp Psiquiatr; 2005; 33(1):19-25. PubMed ID: 15704027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
    Zawertailo LA; Busto UE; Kaplan HL; Greenblatt DJ; Sellers EM
    J Clin Psychopharmacol; 2003 Jun; 23(3):269-80. PubMed ID: 12826989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abuse liability of intra-nasal midazolam in inhaled-cocaine abusers.
    Braun IM; Tavares H; de Nucci G; Bernik M
    Eur Neuropsychopharmacol; 2008 Oct; 18(10):723-8. PubMed ID: 18620849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics.
    Abanades S; Farré M; Segura M; Pichini S; Barral D; Pacifici R; Pellegrini M; Fonseca F; Langohr K; De La Torre R
    Ann N Y Acad Sci; 2006 Aug; 1074():559-76. PubMed ID: 17105953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
    Zacny JP
    Psychopharmacology (Berl); 2003 Jan; 165(2):146-56. PubMed ID: 12404072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
    Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
    J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users.
    Zacny JP
    Drug Alcohol Depend; 2005 Nov; 80(2):273-8. PubMed ID: 16005162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Self-reported drug use and urinalysis results.
    Jain R
    Indian J Physiol Pharmacol; 2004 Jan; 48(1):101-5. PubMed ID: 15270376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pharmacodynamics of diazepam and pentobarbital in substance abusers.
    Sullivan JT; Jasinski DR; Johnson RE
    Clin Pharmacol Ther; 1993 Dec; 54(6):645-53. PubMed ID: 8275619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients.
    Lintzeris N; Mitchell TB; Bond A; Nestor L; Strang J
    J Clin Psychopharmacol; 2006 Jun; 26(3):274-83. PubMed ID: 16702892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subjective and behavioral effects of diazepam depend on its rate of onset.
    de Wit H; Dudish S; Ambre J
    Psychopharmacology (Berl); 1993; 112(2-3):324-30. PubMed ID: 7871037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microemulsion based intranasal delivery system for treatment of insomnia.
    Porecha S; shah T; Jogani V; Naik S; Misra A
    Drug Deliv; 2009 Apr; 16(3):128-34. PubMed ID: 19514972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time series modeling of heroin and morphine drug action.
    Tschacher W; Haemmig R; Jacobshagen N
    Psychopharmacology (Berl); 2003 Jan; 165(2):188-93. PubMed ID: 12404073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of the measurement equivalence of the Childhood Trauma Questionnaire--Short Form across gender and race in a sample of drug-abusing adults.
    Thombs BD; Lewis C; Bernstein DP; Medrano MA; Hatch JP
    J Psychosom Res; 2007 Oct; 63(4):391-8. PubMed ID: 17905047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.